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Abstract Primary antibody deficiencies (PADs) are the
most common primary immunodeficiencies and are char-
acterized by a defect in the production of normal amounts
of antigen-specific antibodies. PADs represent a heteroge-
neous spectrum of conditions, ranging from often asymp-
tomatic selective IgA and IgG subclass deficiencies to the
severe congenital agammaglobulinemias, in which the
antibody production of all immunoglobulin isotypes is
severely decreased. Apart from recurrent respiratory tract
infections, PADs are associated with a wide range of other
clinical complications. This review will describe the
pathophysiology, diagnosis, and treatment of the different
PADs.
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Introduction
Primary antibody deficiencies (PADs) are the most com-
mon primary immunodeficiencies [24]. The hallmark of
PADs is a defect in the production of normal amounts of
antigen-specific antibodies. These antibodies or immuno-
globulins are indispensible for the adaptive immune
response against a wide variety of pathogens. A defect in
antibody production results in recurrent and/or severe
infections. PADs represent a heterogeneous spectrum of
conditions, ranging from often asymptomatic selective IgA
and IgG subclass deficiencies to the severe congenital
agammaglobulinemias, in which antibody production of all
immunoglobulin isotypes is severely decreased. The ma-
jority of patients with symptomatic PADs present with
recurrent ENT and airway infections and are difficult to
discover among the many children presenting to pediatric
practice. Therefore, a diagnostic strategy for immunodefi-
ciency in children has been recently presented in this
journal [16]. Apart from recurrent infections, there is a wide
range of other clinical complications associated with
primary antibody deficiency [13, 15, 43], affecting the
child’s quality of life and life expectancy. After an
introduction on normal B cell development, this review
will describe the pathophysiology, diagnosis, and treatment
of the different PADs.
Normal B cell differentiation and maturation
Plasma cells and memory B cells represent the end stages of B
cell differentiation and maturation (Fig. 1). They are
responsible for the continuous production of specific anti-
bodies and long-lasting immunological memory, respectively
[59]. Memory B cells are able to rapidly differentiate in new
plasma cells in case of reinfections. B cells originate from
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lymphoid precursors in the bone marrow, where a large
repertoire of B cells with different B cell receptors (BCRs) is
formed, consisting of a signaling complex and a membrane
bound IgM molecule. These BCRs are able to recognize a
wide variety of antigens. After leaving the bone marrow,
IgM positive B cells can be activated by antigen and enter a
germinal center in lymphoid tissue. Here, the interaction of B
and T cells, characteristic for the T cell-dependent antibody
response, is contributing to the generation IgG, IgA, and IgE
positive plasmacells and memory B cells by initiation of
class switch recombination (CSR). Somatic hypermutation
(SHM) of the variable region of Ig heavy and Ig light chains
increases the affinity of the BCR for antigen (affinity
maturation). The production of antibodies to polysaccharide
antigens, present in the cell wall of encapsulated bacteria like
pneumococci and meningococci, is supported by a second T
cell-independent B cell response, which localizes in the
marginal zone of the spleen. The T cell-independent B cell
response is still immature in healthy children below the age
of 2 years, hence their susceptibility to severe complications
of pneumococcal and meningococcal infections.
The spectrum of primary antibody deficiencies
Defects in all critical stages of B cell development have
the potential to cause PAD (Fig. 1); however, the
immunological and genetic defects of most patients with
PAD are still unknown. Evaluating a child with a suspected
PAD, the secondary causes for the antibody deficiency,
such as nephrotic syndrome, protein-loosing enteropathy,
use of certain drugs, and hematological malignancies have
to be excluded. Depending on the nature of the B cell
defect, PADs can be separated in different categories
(Table 1), with their own clinical, immunological, and
genetic characteristics. In this section, we will discuss the
different PADs in more detail including specific diagnostic
features and most important clinical complications (Table 2).
Congenital agammaglobulinemias
The first report of a congenital agammaglobulinemia dates
from 1952 [6], when Bruton described a boy with recurrent
infections and a deficiency of gammaglobulins. Many years
later, it appeared that boys with X-linked agammaglobulin-
emia (XLA) suffer from a defect in the gene for Bruton’s
tyrosine kinase or BTK [62], which is crucial for (pre)B cell
receptor signalling. BTK deficiency causes an early block in
B cell development in the bone marrow, resulting in the
(near) absence of B lymphocytes in peripheral blood and
peripheral lymphoid tissues. As a result, antibody produc-
tion of all immunoglobulin isotypes, including the response
to vaccinations is severely impaired. XLA accounts for
85% of all cases of congenital agammaglobulinemia.
Patients with autosomal recessive forms also have B cell
defects affecting the pre-BCR or the downstream signalling
cascade (Fig. 1, Table 1). The clinical problems of these
patients are comparable to XLA, but the clinical phenotype
tends to be more severe because of a more absolute block in
early B cell development [23].
Over half the XLA patients present before 1 year of
age and more than 90% are diagnosed at the age of
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Fig. 1 Antigen(Ag)-independent B cell differentiation occurs in the
bone marrow, whereas Ag-dependent B cell differentiation occurs in
the periphery. After activation by Ag, B cells develop in a T cell-
dependent way in the germinal center and in a T cell-independent way
in the marginal zone of the spleen. Defects of survival, Ag stimulation,
B–T interaction, TI response, CSR/SHM can result in PAD. Identified
PAD genes affecting these processes are indicated
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5 years [66]. Fewer than 10% of the patients have
symptoms in the first 3 months because of protection by
placentally transferred maternal antibodies. Recurrent
ENT and airway infections are the most frequent present-
ing symptoms, but children may also present with severe
bacterial infections in other organ systems [66]. Apart
Table 1 The heterogeneous spectrum of primary antibody deficiencies
Disease Circulating B cells Serum Ig decrease
Congenitial agammaglobulinemias
X-linked
BTK deficiency Severe decrease All isotypes
Autosomal recessive
μ Heavy chain deficiency Severe decrease All isotypes
λ 5 deficiency Severe decrease All isotypes
Ig (or CD79) α deficiency Severe decrease All isotypes
Ig (or CD79) β deficiency Severe decrease All isotypes
BLNK Severe decrease All isotypes
Class switch recombination deficiency
X-linked
CD40 ligand deficiency Normal IgG, IgA
Autosomal recessive
CD40 deficiency Normal IgG, IgA
AID deficiency Normal IgG, IgA
UNG deficiency Normal IgG, IgA
Anhydrotic ectodermal dysplasia with Normal IgG and/or IgA and/or
Immunodeficiency (NEMO deficiency, syndromic) Specific anti-polysaccharide
PMS2 deficiency Normal/decrease IgG variable, IgA
Other PADs with known genetic defect
CD19 deficiency Normal IgG, IgA, and/or IgM
CD81 deficiency Normal IgG, IgA, and/or IgM
ICOS deficiency Normal IgG, IgA, and/or IgM
BAFF receptor deficiency Decrease Variable
TACI deficiency (increased disease susceptibility) Normal Variable
Idiopathic primary antibody deficiencies
Common variable immunodeficiency disordersb Normal/decrease IgG, IgA, and/or IgMc
Possible CVID/CVID-like disorders Normal/decrease IgG
Transient hypogammaglobulinemia of infancy Normal IgG, IgA, and/or IgM
Selective IgM deficiency Normal IgM
Selective IgA deficiencya Normal IgA
IgG2 deficiency
a Normal IgG2
Specific anti-polysaccaride antibody deficiencya Normal Specific anti-polysaccharide
Other PIDs associated with antibody deficiency
Severe combined immunodeficiency Normal/decreased All isotypes
DNA repair disorders Normal/decrease Variable
AD Hyper-IgE syndrome Normal Specific antibodies
Wiscott–Aldrich syndrome Normal IgM, specific anti-polysaccharide
BTK Bruton’s tyrosine kinase, CVID common variable immunodeficiency, TACI transmembrane activator and CAML interactor, AID activation-
induced cytidine deaminase, UNG uracil-n glycosylase, PMST2 postmeiotic segregation increased 2, ICOS inducible costimulator, BAFF B cell-
activating factor, PID pelvic inflammatory disease
a Often combined in one patient
b Can be preceded by conditions marked with a
c Age >2–4 years and decreased response to vaccination
d T-cells show a severe decrease in most patients
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from a severe antibody deficiency, 11% of children with
XLA suffer from concomitant neutropenia, which can be
misdiagnosed as congenital neutropenia. Following the
diagnostic strategy for children with recurrent ENT and
airway infections, congenital agammaglobulinemias can
be easily suspected by low immunoglobulin levels of IgG,
IgA, and IgM [16]. Subsequent lymphocyte subset
analysis will reveal that B cells in the peripheral blood
are severely decreased. In case B cells are present, other
PADs have to be considered, especially transient hypo-
gammaglobulinemia of infancy and class switch recombi-
nation deficiencies (discussed below). When B cells are
absent, a definite diagnosis can be made by genetic
analysis of the candidate genes.
Treatment consists of immunoglobulin replacement
therapy and antibiotic treatment of suspected bacterial
infections. If neutropenia is present, it disappears on
immunoglobulin replacement. Chronic lung disease is the
most frequent long-term complication. XLA patients are
susceptible to chronic enteroviral meningoencephalitis,
which is an important cause of death [66].
Class switch recombination deficiencies
Class switch recombination deficiencies, formerly known
as hyper IgM syndromes, are rare conditions character-
ized by decreased serum IgG and IgA levels, but normal
or increased levels of IgM [28]. The disease-causing
mechanism is either a disturbed co-stimulation of B cells
and T cells in the germinal centre, affecting the initiation
of CSR, or a deregulation of the class switch process itself
(Fig. 1).
The prototype of a co-stimulation defect is X-linked CD40-
ligand deficiency [1, 2, 18, 67]. CD40L deficiency not only
causes a PAD, but also results in a profound T cell deficiency
because the antibody deficiency is secondary to decreased
CD40L expression on T cells. Therefore, CD40L deficiency
is nowadays primarily classified as a T cell disorder [28].
Because of the T cell deficiency, an important difference with
other PADs is the occurrence of opportunistic infections.
Apart from a bacterial pneumonia, which occurs in 80% of
the children, 41% suffer from Pneumocystis jiroveci pneu-
monia [67]. Severe combined immunodeficiency (SCID) is
part of the differential diagnosis of CD40L deficiency (van
der Burg M, Gennery A, the expanding spectrum of severe
combined immunodeficiency, EJP in press), but in contrast
to most cases of SCID, analysis of lymphocyte subpopula-
tion in PAD patients will show normal T cell counts. Similar
to XLA patients, neutropenia can be present and CD40L
patients also share the increased susceptibility chronic
enteroviral meningoencephalitis. Furthermore, CD40L
patients are prone to a fatal sclerosing cholangitis secondary
to a Cryptosporidium parvum infection. Initial treatment
consists of immunoglobulin replacement and Pneumocystis
Clinical complications Predominantly associated with Occurrencea
Recurrent URTI All PAD Very common
Recurrent ENT infections All PAD Very common
Recurrent severe pneumonia Cong. agamma., CSR def., CVID Very common
Bronchiectasis Cong. agamma., CSR def., CVID Common
Interstitial pulmonary abnormalities CVID Rare
Sepsis Cong. agamma., CSR def., CVID Rare
Bacterial osteomyelitis/arthritis Cong. agamma., CSR def., CVID Rare
Bacterial meningitis Cong. agamma., CSR def., CVID Rare
Chronic enteroviral meningoencephalitis Cong.agamma., CD40L def Rare
Recurrent giardiasis All PAD Common
Campylobacter gastroenteritis All PAD Rare
Nodular lymphoid hyperplasia CVID Rare
Inflammatory bowel disease AID, CVID Rare
Enteropathy (chronic diarrhoea of origin) CVID, cong. agamma, sIgAD, AID Common unknown
Autoimmune disease CVID, sIgAD, AID Common
Allergic disorders CVID, sIgAD Common
Granulomas (lung, bowel, other) CVID Rare
(Hepato)splenomegaly CVID Common
Lymphoid hyperplasia CVID, AID Common
Malignancies, Mainly lymphoma CVID Rare
Neutropenia XLA, CD40L Common
Table 2 Clinical complications
of primary antibody deficiency
URTI upper respiratory tract
infection, BTK Bruton’s tyrosine
kinase, AID activation-induced
cytidine deaminase, PAD prima-
ry antibody deficiencies, ENT
cong. agamma congenital
agammaglobulinemias ears,
nose, throat, XLA X-linked
agammaglobulinemia, CVID
common variable immunodefi-
ciency, sIgAD selective IgA de-
ficiency
a Estimated occurrency rate; rare
(<10%), common (10–50%), very
common (>50%)
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jiroveci prophylaxis, but because of the high frequency of
life-threatening complications before the age of 25 years
[36], hematopoietic stem cell transplantation is now the
treatment of choice [19].
A deregulation of the CSR process itself is caused by
AID [45], UNG [27], NEMO [30], and PMS2 [40]
deficiency. X-linked anhidrotic ectodermal dysplasia with
immunodeficiency secondary to mutations in NEMO gives
a much broader immunodeficiency in addition to the CSR
defect and has been described in the EJP review on
syndromic primary immunodeficiencies of Kersseboom et
al. [34] in this journal. The immune defect in AID and
UNG deficiency is limited to the B cell lineage. These
patients usually present at an older age than patients with
CD40L deficiency. Apart from recurrent infections, they
often suffer from lymphoid hyperplasia, inflammatory
bowel disease, and autoimmunity [27, 42].
Common variable immunodeficiency
Common variable immunodeficiency (CVID) is an idio-
pathic antibody deficiency with an estimated prevalence of
1:25,000. It is defined by serum IgG levels below 2 SD of
normal controls in the presence of decreased IgA and/or
IgM levels, recurrent infections, impaired response to
immunization, exclusion of defined causes of hypogamma-
globulinemia, and an age above 2 years (ESID-PAGID-
criteria “probable CVID”, www.esid.org). A considerable
group of patients suffer from a similar idiopathic hypo-
gammaglobulinemia, but do not fulfil all the diagnostic
criteria. These patients are usually diagnosed as “possible”
CVID or as having a “CVID-like” disorder. The clinical
characteristics are indistinguishable from CVID. Less than
10% of the CVID patients have a positive family history
[13] and a genetic defect has only been identified in less
than 10% of the patients who have been reported to the
ESID primary immunodeficiency database with the clinical
phenotype of CVID [24]. Reported defects involve B cell
activation (CD19 [60] and CD81 deficiency [61]), co-
stimulation (ICOS deficiency [25]) and B cell survival
(BAFF-R deficiency [64]). Moreover, genetic defects have
been identified that do not cause hypogammaglobulinemia
per se, but increase disease susceptibility (TACI deficiency
[8, 41, 44, 47, 48]). The heterogeneity of the immunolog-
ical and clinical features of CVID hampers the discovery of
underlying disease-causing mechanisms, clinically relevant
prognostic factors, and genetic defects.
Most of the CVID patients present in young adulthood,
but symptoms start in childhood in more than half of the
cases [43]. Consequently, a diagnostic delay of more than
5 years is the rule [13, 54]. Sometimes CVID is preceded
by IgA deficiency, IgG subclass deficiency, or a specific
anti-polysaccharide antibody deficiency.
The presenting symptoms in CVID are diverse, but
recurrent ENT and airway infections are present in more
than 90% of the patients. Some patients present with
autoimmune disease, most often autoimmune cytopenias
(Table 2). Other clinical features are granulomatous
inflammation of the lungs and gastrointestinal tract, chronic
diarrhoea secondary to unexplained enteropathy, and
haematological malignancies, which are important causes
of death. CVID patients who suffer from at least one non-
infectious complication have higher mortality than patients
who only suffer from infectious complications [9].
Treatment consists of immunoglobulin replacement and
antibiotic treatment of infections. Immunosuppressants are
indicated in some cases with autoimmunity, but therapeutic
guidelines on how to use these agents in CVID patients are
lacking. A low number of switched memory B cells in the
peripheral blood is associated with autoimmunity, granulo-
mas, and respiratory infections [7, 57, 63, 65]. Also,
children who are non-responders to pneumococcal poly-
saccharide vaccination more often suffer from respiratory
infections and bronchiectasis [46]. Growth monitoring is
important because one third of the patients develops a
growth retardation [54], which is associated with recurrent
infectious episodes, but can also develop irrespective of
infectious complications secondary to disturbances of the
growth hormone axis [17, 55]. A combination of short
stature and antibody deficiency may also have its origin in a
syndromic form of primary immunodeficieny [34].
Transient hypogammaglobulinemia of infancy
Transient hypogammaglobulinemia of infancy (THI) has to
be considered in the differential diagnosis of every young
child with hypogammaglobulinemia. It is best defined by
low levels of IgG (<2 SD below the mean for age), with or
without a decrease of IgA or IgM while other causes of the
hypogammaglobulinemia have been excluded [52]. The
pathophysiology is unknown. In some patients, THI might
be a variation of the physiological hypogammaglobuline-
mia secondary to the disappearance of maternal IgG from
the circulations that normally occurs between 3 and 6 month
of age. Many cases probably go unnoticed because they are
asymptomatic. Of the symptomatic cases, most children
present with recurrent ENT and airway infections before the
age of 1 year. Much rarer presenting symptoms are sepsis
[51] or meningitis [26, 50]. Other symptoms include
recurrent diarrhoea, severe varicella infection, or prolonged
oral candidiasis [52]. In more than two thirds of the
children, immunoglobulin levels normalize before the age
of 2 years, but in some children, the condition can persist
up to the age of 5 years [14]. A minority of children will
appear to suffer from a long-lasting PAD. Children who do
not recover from a suspected THI have more infectious
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complications, lower switched memory B cells, and lower
levels of IgM compared to children with a self-limiting
course [38]. Treatment consists of prophylactic antibiotics;
immunoglobulin replacement is usually only given to
patients with severe or frequent infections despite antibiotic
prophylaxis.
Selective IgA, IgG2 subclass, and specific
anti-polysaccharide antibody deficiency
These three PADs are the most prevalent in children and
tend to appear in combination. As single conditions they are
often asymptomatic, but a combination more often leads to
a clinically significant immunodeficiency. This implies that
if one of these conditions is diagnosed, it is useful to search
for the others.
Selective IgA deficiency (sIgAD) is defined as a
decrease of serum IgA <2 SD of age-matched controls.
The prevalence of sIgAD in Europe varies between 1:163
and 1:875 [11, 33]. The incidence is much lower in Asian
populations [32]. Although the cause of sIgAD is unknown,
mutations in TACI increase disease susceptibility, similar to
CVID [44].
Secretory IgA, secreted in the dimeric form, is the
prominent immunoglobulin in luminal secretions of the
respiratory and gastrointestinal tract and as such an
important component of mucosal immunity. Secretory
IgA cannot be measured in the serum; the serum level
of monomeric IgA is rather an indirect reflection of the
level of secretory IgA in the body. The diagnosis of
sIgAD is usually made by analysis of immunoglobulin
levels during the evaluation of recurrent respiratory
infections. However, sIgAD is also often diagnosed “by
accident” as part of a laboratory evaluation for celiac
disease, allergy, or autoimmune disease. The clinical
course is asymptomatic in many patients. If children have
complaints, they usually suffer recurrent ENT and airway
infections. A minority of patients develop recurrent lower
respiratory tract infections and/or bronchiectasis. Patients
with sIgAD are especially at risk of chronic diarrhoea and
giardiasis because of their defect in mucosal immunity.
Furthermore, sIgAD is associated with a higher prevalence
of allergy/atopy and a range of autoimmune diseases,
including autoimmune cytopenias [12, 20, 29].
The four IgG subclasses are defined by the structure of
their constant regions. Of the IgG subclass deficiencies, at
least IgG2 deficiency is clinically relevant. A decrease in
IgG1 cannot be considered as an IgG subclass deficiency a
decrease of IgG1 in it results in hypogammaglobulinemia.
Most patients with IgG3 deficiency also suffer from a
deficiency in another subclass, whereas IgG4 subclass
deficiency is very common, but asymptomatic as a rule.
In healthy children, IgG2 antibodies are low in the first
years of life, after which they gradually increases with age.
Antibodies against encapsulated bacteria are mainly of the
IgG2 subclass, and IgG2 deficiency increased the suscepti-
bility to these bacteria. Children often present with
recurrent respiratory tract and ENT infections. Symptomatic
children with IgG2 subclass deficiency should be tested for
a concomitant specific anti-polysaccharide antibody defi-
ciency (SPAD) if they are older than 2 years [20]. Children
under the age of 10 years may recover spontaneously [52].
If patients continue to experience recurrent respiratory
tract or ENT infections despite normal levels of IgG,
IgA, and IgM, a SPAD has to be excluded. Although the
pathophysiology is unknown, a deficiency of CD20 has
recently been linked to SPAD in one patient [35]. The
antibody response to polysaccharide antigens is impaired
in healthy children under the age of 2 to 3 years, which
contributes to their susceptibility to infections with
encapsulated bacteria. However, some infants are able to
produce normal responses to certain pneumococcal sero-
types [3, 5]. After the age of 2 to 3 years, children should
be able to mount a sufficient response to pneumococcal
polysaccharides. An insufficient response after this age
defines the presence of a SPAD. However, the interpreta-
tion of the pneumococcal serology for the diagnosis of
SPAD is problematic. Jeurissen et al. [31] and Borgers et
al. [4] published the best available serotype-specific cut
off values for anti-pneumococcal antibodies in children
and adults so far. Their fifth percentiles of normal controls
of an ELISA for six different serotypes [31] and a
commercially available bead assay for 14 serotypes [4]
can be used for the diagnosis of SPAD. Pneumococcal
antibodies are measured before and 2 to 4 weeks after
pneumococcal vaccination. Healthy children should be
able to respond to at least seven of the 14 serotypes, above
a level of 0.23 to 1.66 mg l, depending on age and
serotype (Table 3). Furthermore, an increase of two to
fourfold of the pre-vaccination anti-pneumococcal anti-
body level is often used as additional criteria. If children
received previous vaccinations with pneumococcal conju-
gate vaccines, the serotypes present these vaccines cannot
be used for the interpretation of the anti-pneumococcal
polysaccharide response (Table 3), so the introduction of
pneumococcal conjugate vaccines in national vaccination
programs limits the usage of these assays for the diagnosis
of SPAD. The assays measuring the anti-pneumococcal
IgA or IgM response might be able to overcome these
limitations.
Treatment for IgAD, IgG2 deficiency, or SPAD consists
of antibiotic prophylaxis in symptomatic cases, especially
during autumn and winter. If children present with
bronchiectasis or severe recurrent lower respiratory tract
infections, immunoglobulin replacement therapy has to be
considered, especially in case of a combination of sIgAD
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and/or IgG2 deficiency with a SPAD. Data for the efficacy
of immunoglobulin replacement for this indication is
lacking, but clinical studies are ongoing. If diagnosed at
young age, children tend to recover from IgG2, sIgAD, and
SPAD. For individuals diagnosed at an older age, these
conditions are usually permanent. Follow-up with large
intervals is necessary to check for the development of
CVID [21].
Treatment and follow-up of PAD
Immunoglobulin replacement therapy
Before the introduction of immunoglobulin replacement
therapy, the life expectancy of patients with a- or
hypogammaglobulinemia was severely reduced due to
chronic lung disease secondary to recurrent pneumonia
and bronchiectasis. Immunoglobulin replacement prevents
many, but not all, pulmonary complications. Over the past
years, it has become obvious that individual dosing, rather
than supplementation above a certain “through level” of
IgG is necessary to prevent infections complications in
PAD patients [37]. There is no difference in efficacy
between subcutaneous substitution or IV treatment [10].
Home therapy is very well possible and increases the
quality of life [22].
Antibiotic prophylaxis
The use of prophylactic antibiotics to prevent infections in
PAD is widely practiced, but is not evidence based. There is
an urgent need for controlled trials to address this issue
because besides immunoglobulin replacement, it is one of
the few therapeutic options in patients with PAD.
Follow-up and prognosis
The long-term follow-up of PAD patients on immunoglob-
ulin replacement should focus on the early detection of
chronic lung disease. Apart from regularly pulmonary
function tests, it is advisable to perform at least one high
resolution CT thorax in these patients to exclude bronchi-
ectasis or other pulmonary abnormalities [53]. Follow-up
with high resolution low-dose CT thorax is promising, but
needs further evaluation [58]. An increased incidence of
respiratory complications and early onset of disease have
been associated with polymorphisms in mannose-binding
lectin in CVID patients [39], so once a PAD has been
Table 3 Cut off values of antipneumococcal antibodies for the diagnosis of SPAD as defined by Jeurissen et al. [31] and Borgers et al. [4] in
relation to serotypes in pneumococcal conjugate vaccines
Pneumococcal serotype Serotypes of pneumococcal
conjugate vaccine
Anti-pneumococcal
antibodies by ELISA (mg/L)a
Anti-pneumococcal antibodies
by multiplex bead assay (mg/L)a
PCV-7 PCV-10 PCV-13 Age Age Age Age
3–15 years 19–30 years 3–30 years 3–30 years
1 x x 0.53
3 x 0.99 0.58 0.67 0.64
4 x x x 0.73 0.37 0.45 0.49
6B x x x 0.80
7F x x 1.45
8 1.02
9N 0.78 0.23 0.46 0.63
9V x x x 0.69
12F 0.46
14 x x x 0.57
18C x x x 0.55 0.31 0.31 0.34
19A x 0.96
19F x x x 1.66 0.91 1.04 0.74
23F x x x 0.24
Serotypes present in 23-valent pneumococcal polysaccharide (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20,
22F, 23F, and 33F)
a Fifth percentile of normal controls
x serotypes cannot be used for the interpretation of the pneumococcal polysaccharide response, if the child received one of the PCV, PCV
pneumococcal conjugate vaccines, ELISA enzyme-linked immunosorbent assay
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diagnosed, it is useful to check MBL levels. Furthermore,
attention should be paid to symptoms suggesting non-
infectious complications such as autoimmunity, granulo-
mas, splenomegaly, and enteropathy. A decrease of memory
B cells in CVID patients is associated with a higher
incidence of clinical complications [49, 56, 65, 68]. The
use of age-related normal values is important for the
interpretation of the results.
Conclusions, learning points
1. PADs represent a heterogeneous spectrum of condi-
tions, ranging from often asymptomatic selective IgA
and IgG subclass deficiencies to severe congenital
agammaglobulinemias.
2. Patients with PAD most often present with recurrent or
severe respiratory tract and ENT infections.
3. PADs have a range of non-infectious complications,
such as autoimmunity and enteropathy, which might be
the only presenting symptom.
4. Severe PADs can be easily detected by the determina-
tion of total IgG, IgA, and IgM levels.
5. Previous pneumococcal conjugate vaccinations limit
the use of pneumococcal serology for the diagnosis of
specific anti-polysaccharide antibody deficiency.
6. Intravenous or subcutaneous immunoglobulin replace-
ment is the treatment of choice for PAD patients with
reduced IgG levels.
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